



Press Release

Capsulation Expands its Developmental Facilities

New projects on anti-cancer substances

Berlin, August 01th 2006 - In July, Capsulation started to expand its laboratory facilities and thus adapt to the growing customer demand.

The aim is to develop Nanotechnology-based delivery systems for cytotoxic substances, like they are employed in modern cancer therapy. Such active compounds require both special laboratory and occupational health and safety conditions. Therefore, a high development quality and safety standard will be secured by a new, separate working area at Capsulation.

The new laboratory equipment will also be employed for example within the framework of cooperation with AcriTec AG and Schering AG, as was announced in March. According to this cooperation, the companies will concentrate on the development of special hydro-gels that on the one hand have the quality for best possible usage and transport and on the other hand are capable for the controlled release of embedded nanoparticles. These nanoparticles contain active substances and the release of them can take place via a controlled time frame. The combination of functional hydro-gels and embedded nanoparticles enables a targeted release of active substances, which reduces the dosage frequency of the application and increases the therapy safety.

"The extension of the laboratory technology is a vital key to success for our customers and staff alike and at the same time motivates us to further our product development more effectively under the most modern conditions," states Lutz Kröhne, project director at Capsulation. The handling of highly effective new active components (NCEs) will soon be possible too with the help of our new laboratory technology.

Contact person

Capsulation Nanoscience AG

Herr Dipl.-Kfm. Alexander Herrmann

Telefon: +49 (0)30-63 92 36 00

Fax: +49 (0)30-63 92 36 01

alexander.herrmann@capsulation.com



About Capsulation NanoScience AG

Capsulation NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. In order to meet customers needs for complete product solutions Capsulation has recently designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL-units. Only six month after the signing of the licence agreement, EBARA has started operation of the first prototype plant (LBL-Unit®) for the manufacture of Capsulation's LBL capsules. In 2005, renowned growth consultants Frost & Sullivan have awarded the year's "Product Differentiation Innovation Award" in the global nanobiotechnology market to Capsulation NanoScience AG, Berlin. The company has received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Press Release and Press Box online:

<http://www.pressebox.de/pressefach/capsulation-nanoscience-ag>